文献速递痛风与晶体性关节病

秋水仙碱与泼尼松治疗老年急性焦磷酸钙晶体关节炎的安全性与短期等效性评估(COLCHICORT):一项开放标签、多中心、随机试验

Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial.
PubMed 文献 · Lancet Rheumatol · 2023-08-08

COLCHICORT 试验在法国巴黎及北部六家医院纳入65岁及以上、症状持续时间小于36小时的急性焦磷酸钙晶体关节炎住院患者,随机分配至秋水仙碱组(第1天1.5 mg,第2天1 mg)或口服泼尼松组(第1天和第2天各30 mg)。主要结局为24小时关节疼痛视觉模拟量表(VAS)变化,符合方案分析显示两组差值为-1 mm(95%CI -12至10),落在-13 mm至+13 mm等效界值内,表明短期等效;两组安全性特征不同。

要点

  • 24小时疼痛VAS变化:秋水仙碱组-36 mm(SD 32) vs 泼尼松组-38 mm(SD 23),组间差值-1 mm(95%CI -12至10),符合等效界值。
  • 秋水仙碱组55例中12例(22%)发生腹泻,泼尼松组54例中3例(6%)发生腹泻。
  • 泼尼松组报告2例死亡(感染性瓣膜心内膜炎致心力衰竭1例、卒中1例),判定与泼尼松无关;秋水仙碱组无死亡。

核心结论

  • 秋水仙碱与泼尼松对急性焦磷酸钙晶体关节炎的短期疗效等效,但在老年人群中安全性特征不同。

研究设计与样本

  • 开放标签、多中心、随机试验(COLCHICORT),在法国巴黎及北部六家医院开展。
  • 纳入65岁及以上、症状持续时间小于36小时的急性焦磷酸钙晶体关节炎住院患者,滑液分析发现焦磷酸钙晶体或典型临床表现(关节疼痛和肿胀起病)即可诊断。
  • 关键排除标准包括滑液分析无焦磷酸钙晶体或痛风病史。
  • 采用集中式电子治疗分组分配模块按1:1随机分配至秋水仙碱组(第1天1.5 mg,第2天1 mg)或口服泼尼松组(第1天和第2天各30 mg)。
  • 2018年2月5日至2022年5月7日随机分配111例患者(秋水仙碱组57例[51%],泼尼松组54例[49%]),符合方案分析纳入95例(86%)(秋水仙碱组49例[52%],泼尼松组46例[48%])。

主要发现

  • 符合方案分析人群的中位年龄为88.0岁(IQR 82.0-91.0),女性69例(73%),男性26例(27%)。
  • 急性焦磷酸钙晶体关节炎主要累及膝关节46例(48%)、腕关节19例(20%)、踝关节12例(13%)。
  • 基线疼痛VAS为68 mm(SD 17);24小时疼痛VAS变化秋水仙碱组为-36 mm(SD 32),泼尼松组为-38 mm(SD 23)。
  • 24小时疼痛VAS变化的组间差值为-1 mm(95%CI -12至10),显示两药等效。
  • 秋水仙碱组55例中12例(22%)发生腹泻、1例(2%)发生高血压、无高血糖;泼尼松组54例中3例(6%)发生腹泻、6例(11%)发生高血压、3例(6%)发生高血糖。

关键数值与推荐

  • 主要结局为24小时关节疼痛VAS(0 mm至100 mm)变化,等效性判定标准为符合方案分析中24小时组间差值95%CI落在-13 mm至+13 mm界值内。
  • 不良事件采用美国国家癌症研究所不良事件通用术语标准(版本4.0)记录。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute calcium pyrophosphate crystal arthritis causes intense joint pain mainly affecting older people. Because guidance and evidence remain scarce, management of this disease relies on expert opinion. We therefore aimed to compare the safety and short-term equivalence of low-dose colchicine with oral prednisone in older patients with acute calcium pyrophosphate crystal arthritis. METHODS: We did an open-label, multicentre, randomised, trial (COLCHICORT) at six hospitals in Paris and northern France. We enrolled patients who were admitted to hospital who were 65 years or older and who presented with acute calcium pyrophosphate crystal arthritis with a symptom duration of less than 36 h. Diagnosis of calcium pyrophosphate crystal arthritis was made by the identification of calcium pyrophosphate crystals on synovial fluid analysis or typical clinical presentation (onset of joint pain and swelling). Key exclusion criteria included absence of calcium pyrophosphate crystals on synovial fluid analysis or a history of gout. Participants were randomly allocated (1:1), using a centralised electronic treatment group allocation module, to receive either colchicine 1·5 mg on day 1 and 1 mg on day 2 (ie, the colchicine group) or oral prednisone 30 mg on days 1 and 2 (ie, the prednisone group). The primary outcome was change in joint pain (measured by visual analogue scale [VAS] from 0 mm to 100 mm) at 24 h. Equivalence was determined whether the 95% CI of the between-group difference at 24 h was within the -13 mm to +13 mm margin in the per-protocol analysis. Adverse events were recorded using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). This trial is completed and is registered with ClinicalTrials.gov, NCT03128905. FINDINGS: Between Feb 5, 2018, and May 7, 2022, 111 patients who were admitted to hospital were randomly assigned (57 [51%] to the colchicine group and 54 [49%] to the prednisone group). 95 (86%) of 111 patients were included in the per-protocol analysis (49 [52%] in the colchicine group and 46 [48%] in the prednisone group). The median age was 88·0 years (IQR 82·0-91·0) and 69 (73%) of 95 participants were women and 26 (27%) were men. Acute calcium pyrophosphate crystal arthritis affected mainly the knee in 46 (48%) of 95 participants, the wrist in 19 (20%), and the ankle in 12 (13%). Pain VAS at baseline was 68 mm (SD 17). At 24 h, change in pain VAS was -36 mm (SD 32) in the colchicine group and -38 mm (SD 23) in the prednisone group. The between-group difference in change in pain VAS at 24 h was -1 mm (95% CI -12 to 10), showing equivalence between the two drugs. In the colchicine group, 12 (22%) of 55 patients had diarrhoea, one (2%) had hypertension, and none had hyperglycaemia. In the prednisone group, three (6%) of 54 had diarrhoea, six (11%) had hypertension, and three (6%) had hyperglycaemia. No deaths occurred in the colchicine group; two deaths occurred in the prednisone group, which were deemed unrelated to prednisone (one due to infectious valvular endocarditis leading to heart failure, and one due to a stroke). INTERPRETATION: Colchicine and prednisone exhibit equivalent short-term efficacy for the treatment of acute calcium pyrophosphate crystal arthritis, with different safety profiles in the older population. FUNDING: French Inter-regional Hospital Program of Clinical Research.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Pascart T, Robinet P, Ottaviani S, et al. Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial. Lancet Rheumatol. 2023. PMID: 38251496. doi:10.1016/S2665-9913(23)00165-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。